GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lexaria Bioscience Corp (NAS:LEXX) » Definitions » EPS without NRI

LEXX (Lexaria Bioscience) EPS without NRI : $-0.46 (TTM As of Aug. 2024)


View and export this data going back to 2006. Start your Free Trial

What is Lexaria Bioscience EPS without NRI?

Lexaria Bioscience's earnings per share without non-recurring items for the three months ended in Aug. 2024 was $-0.15. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Aug. 2024 was $-0.46.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 28.30% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 18.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Lexaria Bioscience's EPS without NRI or its related term are showing as below:

LEXX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -69   Med: 3.75   Max: 42
Current: 28.3

During the past 13 years, Lexaria Bioscience's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 42.00% per year. The lowest was -69.00% per year. And the median was 3.75% per year.

LEXX's 3-Year EPS without NRI Growth Rate is ranked better than
77.48% of 1239 companies
in the Biotechnology industry
Industry Median: 4.6 vs LEXX: 28.30

Lexaria Bioscience's EPS (Diluted) for the three months ended in Aug. 2024 was $-0.15. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Aug. 2024 was $-0.47.

Lexaria Bioscience's EPS (Basic) for the three months ended in Aug. 2024 was $-0.15. Its EPS (Basic) for the trailing twelve months (TTM) ended in Aug. 2024 was $-0.47.


Lexaria Bioscience EPS without NRI Historical Data

The historical data trend for Lexaria Bioscience's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lexaria Bioscience EPS without NRI Chart

Lexaria Bioscience Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.44 -1.26 -1.11 -0.98 -0.46

Lexaria Bioscience Quarterly Data
Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.10 -0.12 -0.06 -0.13 -0.15

Competitive Comparison of Lexaria Bioscience's EPS without NRI

For the Biotechnology subindustry, Lexaria Bioscience's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lexaria Bioscience's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lexaria Bioscience's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Lexaria Bioscience's PE Ratio without NRI falls into.



Lexaria Bioscience EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Aug. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lexaria Bioscience  (NAS:LEXX) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Lexaria Bioscience EPS without NRI Related Terms

Thank you for viewing the detailed overview of Lexaria Bioscience's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Lexaria Bioscience Business Description

Traded in Other Exchanges
N/A
Address
740 McCurdy Road, No. 100, Kelowna, BC, CAN, V1X 2P7
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.
Executives
Catherine C. Turkel director 19900 MACARTHUR BLVD., SUITE 550, IRVINE CA 92612
Vanessa Carle officer: Secretary 100 - 740 MCCURDY ROAD, KELOWNA A1 V1X 2P7
Gregory Downey officer: Chief Financial Officer 100 - 740 MCCURDY ROAD, KELOWNA A1 V1X 2P7
Christopher Bunka director, 10 percent owner, officer: CEO 1924 BIRKDALE AVE, KELOWNA A1 V1P1R7
Reese Albert L Jr director
Brian W. Quigley director 100 740 MCCURDY ROAD, KELOWNA A1 23230
William Edward Mckechnie director 305 MARGARET AVENUE, KITCHENER A6 N2H 6S4
Allan Horst Spissinger officer: CFO 8131 198A STREET, LANGLEY A1 V2Y 1Y6
John Martin Docherty director, 10 percent owner 23 MIKELEN DRIVE, PORT PERRY A6 L9L 1V1
Baljinder Bhullar director, officer: CFO 604 - 700 WEST PENDER, VANCOUVER A1 V6C 1G8
Nicholas W Baxter director 220 SPRINGFIELD ROAD, ABERDEEN, ABERDEENSHIRE, SCOTLAND X0 AB15 6AU
Dustin Arthur Elford director 888 - 609 WEST HASTINGS STREET, VANCOUVER A1 V6B 4W4
Thomas James Ihrke officer: Sr. VP, Business Development 38 KRIER LANE, MOUNT PLEASANT SC 29464
David Demartini director, 10 percent owner 11714 SPRIGGS WAY, HOUSTON TX 77024
Leonard Macmillan director, officer: Vice President - Corp Develop SUITE 302, 125A - 1030 DENMAN STREET, VANCOUVER A1 V6G 2M6